Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Podophyllotoxin→

Podophyllotoxin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
518-28-5
Molecular formula
C22H22O8
Molecular weight
414.4 g/mol
Drug class
Topical antimitotic lignantubulin-binding microtubule inhibitor
Mechanism of action
Binds tubulin and inhibits its polymerisation, preventing microtubule assembly and arresting dividing cells in metaphase. Local cytotoxicity produces necrosis of HPV-infected wart tissue.
Indications / reported uses
  • Topical treatment of external anogenital warts, including genital and perianal warts, with authorised cream or solution formulations.

Sources: https://www.medicines.org.uk/emc/product/1506/smpc · https://www.cdc.gov/std/treatment-guidelines/anogenital-warts.htm · https://pubchem.ncbi.nlm.nih.gov/compound/10607 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Podophyllotoxin Environmental Risk Assessment (ERA) (the Podophyllotoxin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.